Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 3/2015

01-09-2015 | Case Report

Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients

Author: Chi Long Ho

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2015

Login to get access

Abstract

Tumor-induced osteomalacia (TIO) is a rare disease that manifests with paraneoplasic syndrome and overproduction of fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and hyperphosphaturia, eventually leading to acquired hypophosphatemic osteomalacia. Diagnosis of this disease is often challenging because of the small size of the lesion, which can be localized in bone or soft tissue anywhere in the body. Detecting these occult mesenchymal tumors (OMT) is of great importance as they are potentially curable after tumor resection. The purpose of this case series is to provide some insight into the diagnosis and localization of OMT associated with osteomalacia, particularly using functional imaging with Ga68-DOTA peptide PET/CT scans.
Literature
2.
go back to reference Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.CrossRefPubMed Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.CrossRefPubMed
3.
go back to reference von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH, et al. (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. European Journal of Nuclear Medicine and Mol Imaging. 2008;35:1034.CrossRef von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH, et al. (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. European Journal of Nuclear Medicine and Mol Imaging. 2008;35:1034.CrossRef
4.
go back to reference Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582–3.CrossRefPubMed Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582–3.CrossRefPubMed
5.
go back to reference Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. 2011;17:177–84.CrossRefPubMed Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. 2011;17:177–84.CrossRefPubMed
6.
go back to reference Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Eng J Med. 2003;348:1656–63.CrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Eng J Med. 2003;348:1656–63.CrossRef
7.
go back to reference Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol. 2009;162:1–10.CrossRefPubMed Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol. 2009;162:1–10.CrossRefPubMed
8.
go back to reference Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.CrossRefPubMed Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.CrossRefPubMed
9.
go back to reference Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, et al. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: A case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature. Chin J Cancer. 2011;30:794–804.PubMedCentralCrossRefPubMed Hu FK, Yuan F, Jiang CY, Lv DW, Mao BB, Zhang Q, et al. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: A case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature. Chin J Cancer. 2011;30:794–804.PubMedCentralCrossRefPubMed
10.
go back to reference Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf). 2014;81:31–7.CrossRef Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf). 2014;81:31–7.CrossRef
11.
go back to reference Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36:104–5.CrossRefPubMed Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2009;36:104–5.CrossRefPubMed
12.
go back to reference Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.CrossRefPubMed Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.CrossRefPubMed
13.
go back to reference Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.CrossRefPubMed Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.CrossRefPubMed
14.
go back to reference Cheung FM, Ma L, Wu WC, Siu TH, Choi PT, Tai YP. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. 2006;12:319–21.PubMed Cheung FM, Ma L, Wu WC, Siu TH, Choi PT, Tai YP. Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies. Hong Kong Med J. 2006;12:319–21.PubMed
15.
go back to reference Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33:752–6.CrossRefPubMed Duet M, Kerkeni S, Sfar R, Bazille C, Liote F, Orcel P. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33:752–6.CrossRefPubMed
Metadata
Title
Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients
Author
Chi Long Ho
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2015
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-015-0328-2

Other articles of this Issue 3/2015

Nuclear Medicine and Molecular Imaging 3/2015 Go to the issue